However, our results are not alone; multiple other groups have considered response to anti-PD-1/PD-L1 retrospectively in NSCLC with ECOG performance status 2 and similarly found disappointing response rates, progression-free survival, and OS [21,23]. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.